- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05908838
Clinical Study of Modified Banxia Xiexin Decoction Treatment on Gastric Cancer
June 16, 2023 updated by: Mingyu Sun, ShuGuang Hospital
Randomized Clinical Trial:Clinical Study of Modified Banxia Xiexin Decoction Treatment on Gastric Cancer
Research purpose To elucidate the effect mechanism and clinical effective of Modified Banxia Xiexin Decoction in the prevention and treatment of gastric cancer.
From genes related to cell differentiation, proliferation, apoptosis, tumor invasion and metastasis, genes related to immune inflammation and immune escape and other possible aspects to elucidate the effective and mechanism of Modified Banxia Xiexin Decoction's treatment on gastric cancer
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Modified Banxia Xiexin Decoction treatment and mechanism on Gastric Cancer.
Main Responsibility Person: Mingyu Sun research center#Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Trial Objective#Observe the clinical efficacy and mechanism of Modified Banxia Xiexin Decoction in the treatment gastric cancer Therapeutic Schedule#In this study, 146patients with gastric cancer who received chemotherapy in the Department of Gastrointestinal Surgery and Oncology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine were recruited and divided into groups according to random number table method, namely, 73 patients in the Modified Banxia Xiexin Decoction combined chemotherapy group and 73 patients in the Placebo granules combined chemotherapy group.Modified Banxia Xiexin Decoction group was treated with 18 weeks of Chinese patent medicine Modified Banxia Xiexin Decoction at the same time of chemotherapy.
The Overall survival, Progression-free survival, Solid tumor efficacy, TCM syndrome score, quality of life score, Tumor markers, Immune function and adverse reactions of the two groups before and 18 weeks after treatment were observed and compared.
Elucidate the possible mechanism of action of Modified Banxia Xiexin Decoction in the treatment of gastric cancer patients.
Study Type
Interventional
Enrollment (Actual)
146
Phase
- Early Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with stage IV gastric cancer with a clear cytological or pathological diagnosis.
- The patient is willing to receive palliative chemotherapy (more than 6 months between the first treatment or the last chemotherapy).
- At least one measurable lesion revealed by imaging (PET-CT, CT, MRI, bone scan, x-ray).
- Expected survival of ≥ 6 months.
- It is consistent with the diagnosis of spleen qi deficiency and cold-heat mismatch in TCM.
- Age 18 to 75 years with a physical condition score of ECOG (0-1).
- The blood count is normal, heart, liver and kidney functions are not abnormal, and the electrocardiogram is basically normal.
- Patients have good compliance, are able to understand the study and sign an informed consent form.
Exclusion Criteria:
- Those with a history of severe cardiovascular, urinary, hematological and digestive system diseases.
- Pregnant or breastfeeding women with uncontrollable mental disorders.
- With gastrointestinal obstruction or active bleeding in the gastrointestinal tract, as well as perforation and dysphagia.
- Complications of serious infectious diseases such as active tuberculosis.
- Those with contraindications to chemotherapy or frequent vomiting.
- Poor compliance.
- Patients who have used other trial drugs or in other clinical trials in the past month.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: combination chemotherapy with Modified Banxia Xiexin Decoction
146 patients with gastric cancer were randomly divided into a treatment group of 73 cases and a control group of 73 cases.
The treatment group received combination chemotherapy with Modified Banxia Xiexin Decoction
|
The treatment group#Modified Banxia Xiexin Decoction group#was given Modified Banxia Xiexin Decoction, 2 bags each time, 2 times a day, and 1 hour after meals.
The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and S-1 monotherapy regimen.
|
Placebo Comparator: combination chemotherapy with Placebo granules
The control group received combination chemotherapy with Placebo granules.
|
combination chemotherapy with Placebo granules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: the patients' were included into the clinical trials and up to 18 weeks treatment
|
To observe the effects of treatment group and control group on OS in patients with advanced gastric cancer, and evaluate whether there is statistical difference in OS between the two groups.From date of randomization until the date of death from any cause, whichever came first, assessed up to 18 months.
|
the patients' were included into the clinical trials and up to 18 weeks treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: the patients' were included into the clinical trials and up to 18 weeks treatment
|
The time between the first treatment and tumor progression or death.From date of randomization until the date of first documented progression, whichever came first, assessed up to 18 months.
To observe the effects of treatment group and control group on PFS in patients with advanced gastric cancer, and evaluate whether there is a statistical difference in PFS between the two groups.
|
the patients' were included into the clinical trials and up to 18 weeks treatment
|
EORTC QLQ-C30
Time Frame: the patients' were included into the clinical trials and up to 18 weeks treatment
|
The quality of life score is based on the EuroPean organization for Research and Treatment (EORTC) Quality of Life Scale (QLQ-C30 v3.0), which records changes in quality of life before and after treatment and compares them.
Linear transformation of statistical results was performed to obtain standardized scores (0~100 points), so that scores in various fields could be compared with each other, and the problem of reverse entries could be solved at the same time.
The higher the score of symptom field obtained by each subscale, the worse the quality of life condition.
The higher the scores in the areas of function and general health, the better the patient's quality of life.
Analyze whether there was a statistical difference between the two groups.
|
the patients' were included into the clinical trials and up to 18 weeks treatment
|
Clinical symptoms
Time Frame: the patients' were included into the clinical trials and up to 18 weeks treatment
|
According to the scoring criteria of the Guidelines for Clinical Research of New Chinese Medicines (2002), the symptoms of patients after treatment were determined.
The improvement of patients' overall symptoms was evaluated by Nimodipine method, and the efficacy index after treatment = (total score before treatment - total score after treatment)/total score before treatment *100%.
|
the patients' were included into the clinical trials and up to 18 weeks treatment
|
Tumor markers
Time Frame: the patients' were included into the clinical trials and up to 18 weeks treatment
|
Detect the biomarkers (CA72-4, CEA, CA19-9, CA242, CA50, CA125) of two groups of patients before and after treatment to determine whether there is a statistical difference between the two groups before and after treatment.
|
the patients' were included into the clinical trials and up to 18 weeks treatment
|
Immune function
Time Frame: the patients' were included into the clinical trials and up to 18 weeks treatment
|
T cell subsets of the two groups to determine whether there was a statistical difference between the two groups before and after treatment.
|
the patients' were included into the clinical trials and up to 18 weeks treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mingyu Sun, doctor, Ethics Committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2017
Primary Completion (Actual)
December 1, 2022
Study Completion (Actual)
December 2, 2022
Study Registration Dates
First Submitted
June 8, 2023
First Submitted That Met QC Criteria
June 16, 2023
First Posted (Estimated)
June 19, 2023
Study Record Updates
Last Update Posted (Estimated)
June 19, 2023
Last Update Submitted That Met QC Criteria
June 16, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 42507214-11
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer (Diagnosis)
-
ShuGuang HospitalCompletedGastric Cancer (Diagnosis)
-
Shanghai Jiao Tong University School of MedicineZhongshan Hospital Xiamen University; Nanfang Hospital of Southern Medical... and other collaboratorsUnknownNon-invasive and Sensitive Faecal Bacterial Markers for Early Screening and Diagnosis of Gastric CancerChina
-
Danderyd HospitalRecruiting
-
Zhejiang Cancer HospitalActive, not recruitingGastric Cancer | Diagnosis | Multi-omicsChina
-
Northern Jiangsu People's HospitalCompleted
-
Zhejiang Cancer HospitalWenzhou Medical University; Xijing Hospital; Shanxi Province Cancer Hospital; The... and other collaboratorsRecruitingGastric Cancer | Diagnosis | Tongue ImagesChina
-
University of Colorado, DenverNational Cancer Institute (NCI)Active, not recruitingCouples | Cancer DiagnosisUnited States
-
Case Comprehensive Cancer CenterTerminatedAny Cancer DiagnosisUnited States
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
Massachusetts General HospitalNational Cancer Institute (NCI)RecruitingStress | Distress, Emotional | Cancer DiagnosisUnited States
Clinical Trials on Modified Banxia Xiexin Decoction
-
The University of Hong KongHong Kong Buddhist AssociationCompletedPostprandial Distress SyndromeHong Kong
-
Chinese University of Hong KongActive, not recruitingAtopic DermatitisHong Kong
-
Jun LiUnknown
-
Jun LiNot yet recruitingMyocardial Infarction | Heart Failure
-
Jun LiGuang'anmen Hospital of China Academy of Chinese Medical SciencesUnknown
-
Chongqing Traditional Chinese Medicine HospitalNot yet recruiting
-
Xiyuan Hospital of China Academy of Chinese Medical...RecruitingDiarrhea-predominant Irritable Boewl SyndromeChina
-
Xiyuan Hospital of China Academy of Chinese Medical...Recruiting
-
Chinese University of Hong KongRecruitingAtopic DermatitisHong Kong
-
Beijing University of Chinese MedicineRecruitingModified Zhiwang Decoction Combined With Methotrexate in the Treatment of Early Rheumatoid ArthritisArthritis, RheumatoidChina